NCT00869661 - A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 | Biotech Hunter

Enrollment

413

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions

Hepatitis C, Chronic

Interventions

DRUG

Copegus

1000/1200mg po daily for 24 or 48 weeks

DRUG

Copegus

1000/1200mg po daily for 48 weeks

DRUG

Pegasys

180 micrograms sc weekly for 24 or 48 weeks

DRUG

Pegasys

180 micrograms sc weekly for 48 weeks

DRUG

RO5024048

1000mg bid for 24 weeks

DRUG

RO5024048

500mg bid for 12 weeks

DRUG

RO5024048

1000mg bid for 8 weeks

DRUG

RO5024048

1000mg bid for 12 weeks

Trial Locations (66)

1090

Vienna

2050

Sydney

3004

Melbourne

3065

Fitzroy

4006

Herston

4102

Woolloongabba

4120

Greenslopes

6001

Perth

6009

Nedlands

10021

New York

10126

Turin

13353

Berlin

15006

A Coruña

17033

Hershey

18003

Granada

20037

Washington D.C.

20121

Milan

21093

Lutherville

23249

Richmond

28222

Madrid

29204

Columbia

30060

Marietta

30625

Hanover

33604

Pessac

34209

Bradenton

35294

Birmingham

37211

Nashville

38700

La Tronche

40138

Bologna

41014

Seville

46014

Valencia

54511

Vandœuvre-lès-Nancy

56124

Pisa

59037

Lille

60590

Frankfurt am Main

60637

Chicago

64131

Kansas City

75651

Paris

75679

Paris

77030

Houston

78234

San Antonio

79106

Freiburg im Breisgau

81377

München

89081

Ulm

94010

Créteil

94115

San Francisco

95817

Sacramento

92037-1030

La Jolla

92103-8465

San Diego

32610-0214

Gainesville

07102

Newark

02905

Providence

T2N 4Z6

Calgary

T6G 2B7

Edmonton

V5Z 1M9

Vancouver

V6Z 2K5

Vancouver

N6A 5A5

London

M5G 1L7

Toronto

H2X 3J4

Montreal

06202

Nice

00909

Santurce

08915

Badalona

08003

Barcelona

08036

Barcelona

SE5 9RS

London

W1 1TF

London

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY